Building a Patient-Centric Commercial Model in the Age of AI

Across the industry, more specialty therapies are competing for the same patients than ever before, and as clinical differences between them narrow, patient experience has become one of the few levers left for biopharma companies to stand out commercially. In this Dedicated Dialogue video interview, Courier Health Founder and CEO, Danny Sigurdson, joins Pharmaceutical Executive to unpack why so many companies claim to be patient-centric, but few actually deliver—and what it takes to close that gap.

Drawing on his background building and scaling technology companies, as well as his own experience as a patient, Sigurdson explains why traditional commercial playbooks are struggling to keep pace with today's specialty and rare-disease medicines, and why patient services and market access teams often lack the tools and technology to do their jobs the way they'd like to.

The conversation turns to AI adoption in biopharma, where Sigurdson shares findings from Courier Health's State of Patient-Centricity in Biopharma 2026 report, including that nearly 60% of biopharma companies consider their data fragmented or inactionable, and fewer than 10% have the data maturity to use AI in a meaningful way. He breaks down why access to AI tools doesn't equal adoption, and why the real bottleneck is tying data and technology into actual workflows—with alignment across business, IT, and security and compliance teams.

Sigurdson also discusses how Courier Health approaches AI in its own products and services, what separates "good" companies from "great" ones when it comes to program agility and experimentation, and one shift he believes industry leaders aren't paying enough attention to: treating investment in market access and patient services teams with the same rigor as any other business investment. He closes with an optimistic look at how AI, if built on the right foundation, can free teams to focus on the personalization, empathy, and engagement that matter most to patients.

Key Takeaways:

• Learn why traditional commercial playbooks are breaking down as specialty and rare-disease medicines demand more coordinated, technology-enabled patient support.
• Understand where AI adoption in biopharma really stands today.
• Hear what separates "good" from "great" in patient experience—and how leading biopharma companies build in the agility to course-correct in real time.